https://medlineplus.gov/druginfo/meds/a623063.html
Repotrectinib: MedlinePlus Drug Information
Repotrectinib: learn about side effects, dosage, special precautions, and more on MedlinePlus
medlineplusdruginformation
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive
FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene...
On June 13, 2024, the FDA granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and...
https://pubmed.ncbi.nlm.nih.gov/34482287/?dopt=Abstract
Translational Strategies for Repotrectinib in Neuroblastoma
Limited clinical data are available regarding the utility of multikinase inhibition in neuroblastoma. Repotrectinib (TPX-0005) is a multikinase inhibitor that...
translationalstrategiesneuroblastoma
https://adisinsight.springer.com/drugsafety/803926595?error=cookies_not_supported&code=9bbfa070-b567-47e8-bf8c-dbc30a8e556d
Repotrectinib - AdisInsight
Adults with NTRK fusion-positive advanced solid tumours received repotrectinib and experienced adverse drug reactions, most commonly dizziness, during
adisinsight